[{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Foundation for Angelman Syndrome Therapeutics","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"LB-100","moa":"Protein phosphatase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Foundation for Angelman Syndrome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"Protein phosphatase","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Alliance Global Partners"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lixte Biotechnology \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for LB-100
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
